February 25, 2008European Journal of Endocrinology

Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO

View Full Paper

Ask AI

Bookmark

Intravenous glucocorticoids serve as the primary intervention for active moderate-to-severe Graves' orbitopathy, whereas surgical decompression is reserved for inactive disease.
Consensus guidelines mandate surgical decompression within 1–2 weeks if sight-threatening Graves' orbitopathy fails to improve following intravenous glucocorticoid therapy.
Implications emphasize establishing euthyroidism and referring all patients to specialist centers, ensuring mild cases receive local measures and quality-of-life monitoring.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Consensus statement demonstrates tiered treatment strategies in Graves' orbitopathy patients, highlighting glucocorticoids and prompt surgical decompression.

Cite This Study

Bartalena et al. (2008) studied this question.

synapsesocial.com/papers/69d8c08ace048d2571bee0a8 https://doi.org/10.1530/eje-07-0666

View Full Paper

Ask AI

Bookmark

Implication

Consensus statement demonstrates tiered treatment strategies in Graves' orbitopathy patients, highlighting glucocorticoids and prompt surgical decompression.

Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO

Key Points

Discussion

Implication

Cite This Study

Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider